×

Research and Markets: Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy - Pipeline Review, H2 2012

DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/p8jn7p/angioimmunoblastic) has announced the addition of Global Markets Direct's new report "Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy - Pipeline Review, H2 2012" to their offering.

Global Markets Direct's, 'Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy - Pipeline Review, H2 2012', provides an overview of the Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy therapeutic pipeline. This report provides information on the therapeutic development for Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy.

'Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

Scope:

- A snapshot of the global therapeutic scenario for Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy.

- A review of the Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.

- Coverage of products based on various stages of development ranging from discovery till registration stages.

- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.

- Coverage of the Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy pipeline on the basis of route of administration and molecule type.

- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.

- Key discontinued pipeline projects.

- News and deals relating to the products.

Reasons to Buy:

- Identify and understand important and diverse types of therapeutics under development for Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy.

- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.

- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.

- Devise corrective measures for pipeline projects by understanding Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy pipeline depth and focus of Angioimmunoblastic T-Cell Lymphoma (AILT)/Immunoblastic Lymphadenopathy therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

For more information visit http://www.researchandmarkets.com/research/p8jn7p/angioimmunoblastic

Source: Global Markets Direct

Research and Markets
Laura Wood, Senior Manager.
press@researchandmarkets.com
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Pharmaceuticals

Source: Research and Markets